Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Janssen Pharmaceuticals, Inc. has initiated a voluntary recall of one lot of ORTHO-NOVUM® 1/35 (norethindrone/ethinyl estradiol) Tablets and two lots ...
A new real-world analysis of adults with type 2 diabetes and established cardiovascular disease (CVD) shows adult patients who initiated therapy with ...
Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the 10 mg once-daily dose of XARELTO®...
Janssen Pharmaceuticals, Inc. today announced the recipients of the inaugural HealtheVoices™ Impact Fund grants, supporting innovative efforts by...
Janssen Pharmaceuticals, Inc. (Janssen), today announced real-world evidence showing people with type 2 diabetes initiated on oral INVOKANA®...
Janssen Pharmaceuticals, Inc. today announced the HealtheVoices™ Impact Fund, a new grant offering created to support innovative efforts by online...
Janssen Pharmaceuticals, Inc. (Janssen) today announced it has collaborated with Premier Inc. on the first and largest study of its kind to address...
Janssen Pharmaceuticals, Inc. (Janssen) today announced new Phase 3 results from EINSTEIN CHOICE showing patients with venous thromboembolism (VTE)...
Janssen Pharmaceuticals, Inc. (Janssen) today announced that the company and its development partner, Bayer, will present important new research for...
A new analysis shows people with cancer treated with XARELTO® (rivaroxaban) for blood clots had significantly fewer emergency room (ER) visits and...
New Phase 3b results from the PIONEER AF-PCI study met its primary endpoint and showed that both XARELTO® (rivaroxaban) groups had significantly...
Janssen Pharmaceuticals, Inc. (Janssen) today announced that results from the Phase 3b PIONEER AF-PCI study with XARELTO® (rivaroxaban) and new...
Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer, today announced results of two new real-world studies confirming the...
Janssen Pharmaceuticals, Inc. (Janssen) announced today the U.S. Food and Drug Administration (FDA) has approved INVOKAMET® XR—a once-daily,...
Janssen Pharmaceuticals, Inc., today announced that 25 abstracts have been accepted for presentation by Janssen and its development partner, Bayer,...
Janssen Pharmaceuticals, Inc. (Janssen), today announced real-world and clinical findings showing that people with type 2 diabetes treated with...
Janssen Research & Development, LLC (Janssen), today announced that 18 presentations on INVOKANA® (canagliflozin) will be featured at the American...
Janssen Pharmaceuticals, Inc. (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved INVOKAMET®, a fixed-dose...
Results from three separate data analyses representing diverse patient populations from real-world clinical practice show that use of the once-daily...
The Janssen Pharmaceutical Companies announced that several posters related to Janssen's work in mental health will be featured at the 169th Annual...
Janssen Pharmaceuticals, Inc., and its development partner, Bayer, today announced that 14 data presentations will be presented at the American...
Results of a new analysis of data from real-world clinical practice show that, in adults with type 2 diabetes, use of the once-daily oral medication...
New approach for early treatment and interception of HPV-induced cancers Janssen Pharmaceuticals, Inc. (Janssen) announced today that the company has ...
Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer HealthCare, today announced the first results from CALLISTO, a...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.